bioRxiv Science⌕ Search

Biology subjects

Piper, C.

Publications and source records attributed to Piper, C..

2 recordsLinked to original sources

Multi-step antibody class switching in a primary human response is restricted after IGHG2 and dependent on B cell maturation stage.

Class switch recombination (CSR) allows the formation of functionally specialized antibodies. Understanding of CSR dynamics is key for better design and prediction of vaccines to protect mucosal surfaces. To investigate CSR in a primary human immune response under a controlled setting, we sampled healthy volunteers without COVID-19 history every other day during the first three weeks after SARS-CoV-2 vaccination, with additional time points up to six months. Leveraging bulk and single-cell B cell receptor repertoires, single-cell transcriptomics, and immunophenotyping, we uncover paradigm-shifting insights into CSR. Newly activated B cells produce sterile transcripts of all antibody isotype constant regions (IGHC) simultaneously up to IGHG2, challenging the view that sterile transcription occurs for only a single IGHC gene at a time. CSR follows a multistep progression along the IGHC locus; in this challenge vaccine-induced B cells switch from IGHM to IGHG3 and IGHG1, followed by a subsequent switching to IGHA1 and IGHG2 after secondary immunization. IGHA2 clones require pre-switching to IGHA1 clones. Notably, switching tendency, measured by IGHC sterile transcription, is memory B cell subtype dependent, particularly beyond IGHG2. Contrary to other vaccines, antigen-specific B cells are enriched in DN2, Cmem2 and DN4 subtypes after immunization. We also observe a temporal decoupling of CSR and somatic hypermutation (SHM), with the latter detectable only after six months post-immunization. Our data describes the dynamics between CSR, SHM, sterile transcription and B cell memory development during a human primary response, challenges textbook models of CSR and offers new insights to aid control of CSR direction. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=188 HEIGHT=200 SRC="FIGDIR/small/652638v1_ufig1.gif" ALT="Figure 1"> View larger version (49K): org.highwire.dtl.DTLVardef@785769org.highwire.dtl.DTLVardef@b2c54eorg.highwire.dtl.DTLVardef@b78c72org.highwire.dtl.DTLVardef@65b5aa_HPS_FORMAT_FIGEXP M_FIG C_FIG One Sentence SummaryClass switch recombination occurs independently of somatic hypermutation and in a multistep fashion up to IGHG2 during a primary response in humans.

immunology↗

KDM6A Regulates Immune Response Genes in Multiple Myeloma

The histone H3K27 demethylase KDM6A is a tumor suppressor in multiple cancers, including multiple myeloma (MM). We created isogenic MM cells disrupted for KDM6A and tagged the endogenous protein to facilitate genome wide studies. KDM6A binds genes associated with immune recognition and cytokine signaling. Most importantly, KDM6A binds and activates NLRC5 and CIITA encoding regulators of Major Histocompatibility Complex (MHC) genes. Patient data indicate that NLRC5 and CIITA, are downregulated in MM with low KDM6A expression. Chromatin analysis shows that KDM6A binds poised and active enhancers and KDM6A loss led to decreased H3K27ac at enhancers, increased H3K27me3 levels in body of genes bound by KDM6A and decreased gene expression. Reestablishing histone acetylation with an HDAC3 inhibitor leads to upregulation of MHC expression, offering a strategy to restore immunogenicity of KDM6A deficient tumors. Loss of Kdm6a in murine RAS-transformed fibroblasts led to increased growth in vivo associated with decreased T cell infiltration. Statement of significanceWe show that KDM6A participates in immune recognition of myeloma tumor cells by directly regulating the expression of the master regulators of MHC-I and II, NLRC5 and CIITA. The expression of these regulators can by rescued by the HDAC3 inhibitors in KDM6A-null cell lines.

cancer biology↗